EA032429B1 - Селективные низкомолекулярные ингибиторы cdk8/cdk19 и их применение в качестве агентов для лечения рака - Google Patents

Селективные низкомолекулярные ингибиторы cdk8/cdk19 и их применение в качестве агентов для лечения рака Download PDF

Info

Publication number
EA032429B1
EA032429B1 EA201791284A EA201791284A EA032429B1 EA 032429 B1 EA032429 B1 EA 032429B1 EA 201791284 A EA201791284 A EA 201791284A EA 201791284 A EA201791284 A EA 201791284A EA 032429 B1 EA032429 B1 EA 032429B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
compounds
disease
molecular weight
low molecular
Prior art date
Application number
EA201791284A
Other languages
English (en)
Russian (ru)
Other versions
EA201791284A1 (ru
Inventor
Игорь Ронинсон
Дональд Си. Портер
Марк Пи. Уэнтланд
Original Assignee
Сенекс Биотекнолоджи Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сенекс Биотекнолоджи Инк. filed Critical Сенекс Биотекнолоджи Инк.
Publication of EA201791284A1 publication Critical patent/EA201791284A1/ru
Publication of EA032429B1 publication Critical patent/EA032429B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
EA201791284A 2012-02-02 2013-02-01 Селективные низкомолекулярные ингибиторы cdk8/cdk19 и их применение в качестве агентов для лечения рака EA032429B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261594023P 2012-02-02 2012-02-02
US201261673419P 2012-07-19 2012-07-19

Publications (2)

Publication Number Publication Date
EA201791284A1 EA201791284A1 (ru) 2017-10-31
EA032429B1 true EA032429B1 (ru) 2019-05-31

Family

ID=47716178

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201791284A EA032429B1 (ru) 2012-02-02 2013-02-01 Селективные низкомолекулярные ингибиторы cdk8/cdk19 и их применение в качестве агентов для лечения рака
EA201491399A EA028595B1 (ru) 2012-02-02 2013-02-01 Селективные ингибиторы cdk8/cdk19 и их применение в качестве противометастатических и химиопрофилактических агентов для лечения рака

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201491399A EA028595B1 (ru) 2012-02-02 2013-02-01 Селективные ингибиторы cdk8/cdk19 и их применение в качестве противометастатических и химиопрофилактических агентов для лечения рака

Country Status (16)

Country Link
US (2) US9321737B2 (enExample)
EP (2) EP2809324B1 (enExample)
JP (1) JP6193268B2 (enExample)
KR (1) KR20150023223A (enExample)
CN (1) CN104363913B (enExample)
AU (1) AU2013214783B2 (enExample)
BR (1) BR112014019052A8 (enExample)
CL (1) CL2014002062A1 (enExample)
CO (1) CO7151516A2 (enExample)
EA (2) EA032429B1 (enExample)
GE (2) GEP201706688B (enExample)
MY (1) MY165446A (enExample)
PH (1) PH12014501862A1 (enExample)
SG (1) SG11201404596UA (enExample)
UA (1) UA117342C2 (enExample)
WO (1) WO2013116786A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015001613B1 (pt) * 2012-07-27 2021-02-23 Biogen Ma Inc compostos que são agentes de modulação de s1p e/ou agentes de modulação de atx, seus usos e composição farmacêutica
KR20150044952A (ko) * 2012-08-23 2015-04-27 에프. 호프만-라 로슈 아게 암의 치료를 위한 신규한 페닐-피리딘/피라진 아미드
JP6310470B2 (ja) 2012-11-01 2018-04-11 ユニバーシティ オブ サウス カロライナ 前立腺がんを処置するための方法
EP2961409A1 (en) * 2013-02-26 2016-01-06 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
SG11201605178WA (en) 2013-12-24 2016-07-28 Harvard College Cortistatin analogues and syntheses and uses thereof
WO2015159938A1 (ja) * 2014-04-18 2015-10-22 武田薬品工業株式会社 複素環化合物
EP3154952A4 (en) * 2014-06-10 2018-03-14 University of South Carolina Methods and compositions for treatment of her-positive cancers
US20210322651A1 (en) 2014-12-18 2021-10-21 Senex Biotechnology, Inc. Suppression of neointimal formation following vascular surgeru using cdk8 inhibitors
WO2016182932A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
KR20180003597A (ko) * 2015-05-08 2018-01-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 코르티스타틴 유도체로의 치료를 위한 환자의 표적화된 선택
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
BR112018008931A8 (pt) 2015-11-03 2019-02-26 Lu License Ab ?compostos para tratamento de distúrbios hipoproliferativos?
WO2017091836A1 (en) * 2015-11-25 2017-06-01 University Of South Carolina Enhancement of cytarabine activity by inhibiting cdk8/19
WO2017164230A1 (ja) * 2016-03-23 2017-09-28 国立大学法人 岡山大学 リン酸化ｓａｒｍ１、抗体、ｓａｒｍ１リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、ｓａｒｍ１改変体及び使用
US11285144B2 (en) 2016-08-03 2022-03-29 The Broad Institute, Inc. Use of CDK8 inhibitors to treat diseases of inflammation and autoimmunity
JP7142846B2 (ja) 2017-01-30 2022-09-28 国立大学法人京都大学 新規化合物及び制御性ｔ細胞の製造方法
WO2018151633A1 (ru) * 2017-02-20 2018-08-23 Закрытое Акционерное Общество "Биокад" Способы получения производных 4-(((нафталин-2-ил)алкил)амино)хинозалин-6-карбонитрилов
WO2018156858A1 (en) * 2017-02-23 2018-08-30 University Of South Carolina Use of cdk8/19 inhibitors for treatment of established colon cancer hepatic metastasis
EP3591040A4 (en) 2017-03-03 2020-11-11 Kyoto University METHOD OF PRODUCTION OF PANCREATIC PROGENITOR CELLS
WO2018186366A1 (ja) * 2017-04-03 2018-10-11 京都薬品工業株式会社 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤
RU2641001C1 (ru) * 2017-04-03 2018-01-15 Закрытое Акционерное Общество "Биокад" Соли 4-((2-(6-(4-метилпиперазин-1-карбонил)нафталин-2-ил)этил)амино)хиназолин-6-карбонитрила и фармацевтическая композиция
AU2018333072B2 (en) * 2017-09-18 2022-09-29 Cz Biohub Sf, Llc Methods for treating triple-negative breast cancer
CN111163775B (zh) 2017-10-02 2023-07-11 勃林格殷格翰国际有限公司 作为cdk8/cdk19抑制剂的新型[1,6]萘啶化合物和衍生物
RU2763347C2 (ru) * 2018-03-01 2021-12-28 Закрытое Акционерное Общество "Биокад" Новые ингибиторы cdk8/19
US11014906B2 (en) 2018-08-21 2021-05-25 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
US12281080B2 (en) 2018-08-21 2025-04-22 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
ES2991429T3 (es) 2019-02-01 2024-12-03 Univ South Carolina Compuestos de piridina bicíclicos para su uso en el tratamiento del cáncer
CN116391028A (zh) 2020-11-20 2023-07-04 千纸鹤治疗公司 促熟剂
TW202246489A (zh) 2021-02-09 2022-12-01 日商千紙鶴治療公司 成熟化劑
WO2022204534A1 (en) * 2021-03-25 2022-09-29 University Of South Carolina Cdk8/19 inhibitors for the treatment of cytokine storm
EP4410965A4 (en) 2021-09-27 2025-09-24 Univ Kyoto T LYMPHOCYTE PRODUCTION PROCESS
KR20240130083A (ko) 2021-11-24 2024-08-28 레그셀 가부시키가이샤 T세포 관련 질환을 치료 또는 예방하기 위한 의약 조성물
TW202330911A (zh) 2021-11-24 2023-08-01 日商雷格細胞股份有限公司 人類誘導性控制性ｔ細胞及其製作方法
EP4497822A4 (en) 2022-03-23 2026-03-18 Univ Kyoto PROCESS FOR THE PRODUCTION OF REGULATORY T LYMPHOCYTES
IL315122A (en) 2022-04-25 2024-10-01 Orizuru Therapeutics Inc Maturing agent having both of alk5 inhibitory activity and cdk8/19 inhibitory activity
CA3251059A1 (en) 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Compositions, systems and methods for modulating a target gene
CN119546748A (zh) 2022-07-14 2025-02-28 千纸鹤治疗公司 细胞移植用纤维蛋白凝胶片
EP4596684A1 (en) 2022-09-26 2025-08-06 Regcell Co., Ltd. Induced regulatory t cells containing chimeric antigen receptor (car)
CN120112629A (zh) 2022-09-26 2025-06-06 国立大学法人京都大学 T细胞产生方法
US20260232799A1 (en) 2023-02-08 2026-08-13 Regcell Co., Ltd. Pharmaceutical composition for treating or preventing pemphigus
CN121057812A (zh) 2023-03-29 2025-12-02 雷格细胞股份有限公司 人诱导性调节性t细胞及其制作方法以及用于治疗或预防t细胞相关疾病的药物组合物
TWI858946B (zh) 2023-10-03 2024-10-11 臺北醫學大學 辨識量化系統及其運作方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US20040204409A1 (en) * 2003-04-10 2004-10-14 Kazuo Ando Bicyclic compounds as NR2B receptor antagonists
US20080033000A1 (en) * 2006-05-15 2008-02-07 Senex Biotechnology, Inc. Identification of CDKI pathway inhibitors
US20120071477A1 (en) * 2009-11-30 2012-03-22 Senex Biotechnology, Inc. Cdki pathway inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1158269C (zh) * 1997-10-27 2004-07-21 阿古龙制药公司 作为cdk抑制剂的取代的4-氨基-噻唑-2-基化合物
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
US20040180844A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
US20040180848A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US20040204409A1 (en) * 2003-04-10 2004-10-14 Kazuo Ando Bicyclic compounds as NR2B receptor antagonists
US20080033000A1 (en) * 2006-05-15 2008-02-07 Senex Biotechnology, Inc. Identification of CDKI pathway inhibitors
US20120071477A1 (en) * 2009-11-30 2012-03-22 Senex Biotechnology, Inc. Cdki pathway inhibitors and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. C. PORTER, E. FARMAKI, S. ALTILIA, G. P. SCHOOLS, D. K. WEST, M. CHEN, B.-D. CHANG, A. T. PUZYREV, C.-U. LIM, R. ROKOW-KITTELL,: "Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 34, 21 August 2012 (2012-08-21), pages 13799 - 13804, XP055056523, ISSN: 00278424, DOI: 10.1073/pnas.1206906109 *
VICTOR���J. CEE, DAVID���Y.-K. CHEN, MATTHEW���R. LEE, K.���C. NICOLAOU: "Cortistatin���A is a High-Affinity Ligand of Protein Kinases ROCK, CDK8, and CDK11", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, �VERLAG CHEMIE| :, vol. 48, no. 47, 9 November 2009 (2009-11-09), pages 8952 - 8957, XP055056483, ISSN: 14337851, DOI: 10.1002/anie.200904778 *

Also Published As

Publication number Publication date
US9321737B2 (en) 2016-04-26
JP6193268B2 (ja) 2017-09-06
US20170071942A1 (en) 2017-03-16
KR20150023223A (ko) 2015-03-05
WO2013116786A1 (en) 2013-08-08
EA201791284A1 (ru) 2017-10-31
JP2015506376A (ja) 2015-03-02
EP2809324B1 (en) 2018-08-01
GEP20186818B (en) 2018-02-12
MY165446A (en) 2018-03-22
BR112014019052A2 (enExample) 2017-06-20
UA117342C2 (uk) 2018-07-25
EA028595B1 (ru) 2017-12-29
CO7151516A2 (es) 2014-12-29
PH12014501862A1 (en) 2014-11-24
AU2013214783A1 (en) 2014-08-28
CN104363913B (zh) 2018-08-21
SG11201404596UA (en) 2014-10-30
CN104363913A (zh) 2015-02-18
GEP201706688B (en) 2017-06-26
EA201491399A1 (ru) 2015-04-30
EP2809324A1 (en) 2014-12-10
CL2014002062A1 (es) 2015-03-20
EP3431087A1 (en) 2019-01-23
AU2013214783B2 (en) 2017-07-06
US10993945B2 (en) 2021-05-04
US20140038958A1 (en) 2014-02-06
BR112014019052A8 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
JP6193268B2 (ja) Ｃｄｋ８／ｃｄｋ１９選択的阻害剤、ならびに癌のための抗転移および化学防御の方法におけるそれらの使用
Humphries-Bickley et al. Characterization of a dual Rac/Cdc42 inhibitor MBQ-167 in metastatic cancer
KR20170001962A (ko) 항 악성 종양제 조성물
EP2687216B1 (en) Pharmaceutical composition for treating aging-associated diseases, containing progerin expression inhibitor as active ingredient, and screening method of said progerin expression inhibitor
Sun et al. A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis, and sensitizes lung cancer cells to chemotherapy
CN108309982A (zh) 3位取代的5H-[1,2,4]三嗪[5,6-b]吲哚衍生物的用途
US20090005398A1 (en) Methods For The Treatment of Central Nervous System Tumors
US12258360B2 (en) Compositions and methods for treatment of anticancer-drug resistant cancers
US20210238140A1 (en) Compounds for Targeting Cancer Stem Cells
Wu et al. B13, a well-tolerated inhibitor of hedgehog pathway, exhibited potent anti-tumor effects against colorectal carcinoma in vitro and in vivo
Cseke et al. Propafenone analogue with additional H‐bond acceptor group shows increased inhibitory activity on P‐glycoprotein
US9775833B2 (en) Method for the treatment of NF1- or RAS-associated disorders
US20210353631A1 (en) 1,4-Benzoxazines for the Treatment of Cancers and Other Neurodegenerative Diseases
Wang et al. A novel L-shaped ortho-quinone analog targeting adenosine A2b receptor to inhibit epithelial-mesenchymal transition in colorectal cancer cells
US20250122193A1 (en) Novel pyridocarbazolium compounds and medical uses thereof
Liu et al. RNA binding motif protein RBM41 promotes colorectal tumorigenesis by impeding the maturation of NDRG1 pre-mRNA
WO2019074895A1 (en) COMPOUNDS FOR INHIBITING SECRETORY LEUKOCYTE PROTEIN INHIBITOR (SLPI)
RU2789449C2 (ru) Способ прогнозирования терапевтического эффекта ингибитора lsd1 на основе экспрессии insm1
CN117843635A (zh) Hotair抑制剂及其医药用途
JP2023530734A (ja) アイソフォーム特異的アルデヒドデヒドロゲナーゼ阻害剤
US20210379077A1 (en) Topoisomerase ii catalytic inhibitor compound therapeutics for cancer treatment, methods and uses
WO2024015641A1 (en) Small molecule for treatment of cancer of the appendix
CN121159528A (zh) 一种PROTAC化合物及其制备方法和作为靶向PTRF/Cavin1的降解剂的应用
JP2006348021A (ja) 細胞周期阻害剤
Gu et al. Design, synthesis and anticancer activity of novel 6-substituted-1-(3, 4, 5-trimethoxyphenyl)-1H-indole against tubulin polymerisation

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU